Rainbow Rare Earths Phalaborwa project shaping up to be one of the lowest cost producers globally. Watch the video here.
"regail"
There is no such word bon scott
Bon Scott still waiting for you to justify the ridiculous "dilution galore" from the other day. And apologise for your misleading post about the 15m new shares being issued. Which they weren't
Maybe someone who actually has an investment here could comment on the incentive plan, as they will be able to vote.
Unlike the remaining three idiots who are just spouting away per normal
So just had a quick read through of the notification of AGM
Apparently, to see the details of the proposed new incentive scheme, you need to go to Dale Street
I'm voting against as a point of principle
Not surprising, the project is rapidly derisking, the scale is increasing, the only surprise is the frankly ridiculous sp rise given the scale of the buying.
To be still lower than Hainan buy in price is plain daft
What an RNS.
Potentially ahead of time and budget
Resource looking like it will be massively extended.
The company embedding itself in the local community and economy
Got to love how Bernie is going about this
Wyndrum once again you are spinning a yarn.
The RNS you refer to simply stated the test had received a CE mark. It didn't state the test had been taken to market. It said Medusa had world wide rights to it, not that they had launched it.
So once again you are positioning untruths to support a negative story
Do you know how effective any of the Chinese tests were for Omicron?
Avacta didn't withdraw the test as you know. You can't withdraw something that isn't on sale.
It seems you are accusing others of making stuff up when, in point of fact, that is exactly what you are doing
I guess the key thing is to set your own exit strategy and then to stick with it.
Once I'm gone, I'm gone and don't look back. Sellers remorse is the worst thing.
Aim shares I like to clear my initial investment as quickly as possible and then free carry.
Not there yet here lol
No wyndrum what i said was it was never marketed for home use. So it was never "real world" tested in the way that diagnostics has been.
Why so angry Smalley, simply because somebody questions your motives.
Truly you are a very small person.
I have no wish for you to do any research for me, I'm happy with my own. What i would like you to do is back up the posts you make. Because i know you lie and are purely agenda driven.
The fact you won't do so speaks volumes, to me atleast
Wyndrum you make my point for me.
You have chosen to post from an RNS that came after government policy had stopped any potential marketing of the test for home use. and barely a month before Avacta pulled the product and before Medusa were able to even launch it.
So you are once again far from the whole truth.
Southcoast
Not in asos, it's turn around isn't far enough progressed for me yet.
Precious metals and Lithium for me mostly atm
Bon Scott, whose post is this?
Hexam, never explain a single thing to coasty. Just a sick parasite, who adds no value whatsoever.
Wow that could be the silliest post i have seen this year
Nicetomichu, to refresh your memory. This is what i asked Smalley to provide the link to. I'd agree he knows a lot of detail, what he wishes to use it for is a totally different question. It seems strange that somebody won't share this information, which is exactly what boards like this are meant to be for.
The company (Harvest) does provide via electronic invoices (DANFE/boleto) individual sales invoice details to ANM for tax collection purposes.
The ANM does produce month by month tax, revenue and in some cases tonnage for all these transactions.
Wyndrum you know that isn't quite true, or even anywhere near the total truth.
Yes the LFT was licensed for professional use and sold a few. and apparently worked effectively for the original covid and variants. However, it was never released for home use in the UK for various reasons, mainly political,which would be my definition of market launch.
So we know that the platform technology actually worked on diagnostics and therapeutics. We know that so far there is a beneficial effect on a small number of trial patients in the real world. So that is as far as the comparison between the two goes.
I'm surprised anybody would see the greater number of cohorts to find a MTD a bad thing, as this simply shows the product is working better than original expectations
Only just gone over half a million, it's genuinely pathetic
Thornogson
Firstly I don't categorise anybody as idiots or non idiots. It's just plain rude and does nothing to encourage an actual debate.
You are correct, there is a significant mismatch between a European fund paying 50p and the current continuing share price decline.
If you understand statistics at all, you can see the platform is doing what it is meant to be doing. We are seeing a rolled up version of lots of core data. So far it is doing exactly what it is meant to do.
I'm very careful with the words I use. I'm not saying it works full stop. The early indications are that it works for some cancers but it is by no means certain how well yet.
Why anybody would expect any more from a safety trial is beyond me.
So we have moved downwards by about 70% in sp terms whilst the trial has done what it is meant to do.
Plain daft.
Some posters seem to wish to see the sp as the be and all, as if markets were fair, rational and open. They aren't
They also wish to compare Ava6000 to the LFT, a product which never even got to market. Why anybody would do that is also beyond me. It's chalk and cheese.
As I keep saying Jeremy, it's all about Frasers
Who the trolls said had given up buying.
Strange friend Hexam has nothing to say about that one either
So glad you agree that revenue is up compared to PRECOVID, which until this year is the only valid comparator.
Read the posts Hexam, I haven't made a comparison Boo Vs M&S. It would be a spurious comparison. My point was in response to the troll stupidity and purely in relation to M&S moving their stores away from the high st which they undoubtedly have.
If you are unable to see the Boo strategy playing out then why not sell up.
You don't think rampant inflation, cost of living crisis and the reduction in the COVID online bubble, which is now reversing, are the major impactors on performance here.
Strange you are unable to attempt to correct any troll nonsense here, ever.
Each to their own
I agree Thornogson that all sides should be heard, its what makes a BB valuable.
However the sp decline here has nothing to do with the performance of AVA6000 in trial, which is progressing as well as could have been envisaged. It's all to do with shorts who are trying to do here what they did to SAR, as i've posted here multiple times over the past couple of months. Sadly, with the lack of oversight on AIM they are currently winning, which is a sick joke.
I've sold most of mine with a view to reinvesting when the slow crawl down stops, which it assuredly will at some point.
Because ultimately the drug and platform is doing exactly what it was supposed to do